213 related articles for article (PubMed ID: 21186796)
1. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.
Zhang Z; Wallace MB; Feng J; Stafford JA; Skene RJ; Shi L; Lee B; Aertgeerts K; Jennings A; Xu R; Kassel DB; Kaldor SW; Navre M; Webb DR; Gwaltney SL
J Med Chem; 2011 Jan; 54(2):510-24. PubMed ID: 21186796
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors.
Lam B; Zhang Z; Stafford JA; Skene RJ; Shi L; Gwaltney SL
Bioorg Med Chem Lett; 2012 Nov; 22(21):6628-31. PubMed ID: 23025999
[TBL] [Abstract][Full Text] [Related]
3. Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.
Nishio Y; Kimura H; Tosaki S; Sugaru E; Sakai M; Horiguchi M; Masui Y; Ono M; Nakagawa T; Nakahira H
Bioorg Med Chem Lett; 2010 Dec; 20(24):7246-9. PubMed ID: 21074430
[TBL] [Abstract][Full Text] [Related]
4. Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors.
Park WS; Kang SK; Jun MA; Shin MS; Kim KY; Rhee SD; Bae MA; Kim MS; Kim KR; Kang NS; Yoo SE; Lee JO; Song DH; Silinski P; Schneider SE; Ahn JH; Kim SS
Bioorg Med Chem Lett; 2011 Mar; 21(5):1366-70. PubMed ID: 21306895
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.
Wallace MB; Feng J; Zhang Z; Skene RJ; Shi L; Caster CL; Kassel DB; Xu R; Gwaltney SL
Bioorg Med Chem Lett; 2008 Apr; 18(7):2362-7. PubMed ID: 18346892
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors.
Li N; Wang LJ; Jiang B; Guo SJ; Li XQ; Chen XC; Luo J; Li C; Wang Y; Shi DY
Bioorg Med Chem Lett; 2018 Jul; 28(12):2131-2135. PubMed ID: 29773502
[TBL] [Abstract][Full Text] [Related]
7. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
9. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Mattei P; Boehringer M; Di Giorgio P; Fischer H; Hennig M; Huwyler J; Koçer B; Kuhn B; Loeffler BM; Macdonald A; Narquizian R; Rauber E; Sebokova E; Sprecher U
Bioorg Med Chem Lett; 2010 Feb; 20(3):1109-13. PubMed ID: 20031405
[TBL] [Abstract][Full Text] [Related]
10. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.
Tsai TY; Hsu T; Chen CT; Cheng JH; Chiou MC; Huang CH; Tseng YJ; Yeh TK; Huang CY; Yeh KC; Huang YW; Wu SH; Wang MH; Chen X; Chao YS; Jiaang WT
Bioorg Med Chem Lett; 2009 Apr; 19(7):1908-12. PubMed ID: 19269819
[TBL] [Abstract][Full Text] [Related]
11. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
Feng J; Zhang Z; Wallace MB; Stafford JA; Kaldor SW; Kassel DB; Navre M; Shi L; Skene RJ; Asakawa T; Takeuchi K; Xu R; Webb DR; Gwaltney SL
J Med Chem; 2007 May; 50(10):2297-300. PubMed ID: 17441705
[TBL] [Abstract][Full Text] [Related]
12. Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.
Sutton JM; Clark DE; Dunsdon SJ; Fenton G; Fillmore A; Harris NV; Higgs C; Hurley CA; Krintel SL; MacKenzie RE; Duttaroy A; Gangl E; Maniara W; Sedrani R; Namoto K; Ostermann N; Gerhartz B; Sirockin F; Trappe J; Hassiepen U; Baeschlin DK
Bioorg Med Chem Lett; 2012 Feb; 22(3):1464-8. PubMed ID: 22177783
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group.
Kondo T; Nekado T; Sugimoto I; Ochi K; Takai S; Kinoshita A; Hatayama A; Yamamoto S; Kishikawa K; Nakai H; Toda M
Bioorg Med Chem; 2008 Feb; 16(4):1613-31. PubMed ID: 18039579
[TBL] [Abstract][Full Text] [Related]
14. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Kim HJ; Kwak WY; Min JP; Lee JY; Yoon TH; Kim HD; Shin CY; Kim MK; Choi SH; Kim HS; Yang EK; Cheong YH; Chae YN; Park KJ; Jang JM; Choi SJ; Son MH; Kim SH; Yoo M; Lee BJ
Bioorg Med Chem Lett; 2011 Jun; 21(12):3809-12. PubMed ID: 21570283
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125.
Miyamoto Y; Banno Y; Yamashita T; Fujimoto T; Oi S; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Amano M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
Bioorg Med Chem; 2011 Jan; 19(1):172-85. PubMed ID: 21163664
[TBL] [Abstract][Full Text] [Related]
16. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors.
Zhu Y; Xia S; Zhu M; Yi W; Cheng J; Song G; Li Z; Lu P
Eur J Med Chem; 2010 Nov; 45(11):4953-62. PubMed ID: 20800322
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
Madar DJ; Kopecka H; Pireh D; Yong H; Pei Z; Li X; Wiedeman PE; Djuric SW; Von Geldern TW; Fickes MG; Bhagavatula L; McDermott T; Wittenberger S; Richards SJ; Longenecker KL; Stewart KD; Lubben TH; Ballaron SJ; Stashko MA; Long MA; Wells H; Zinker BA; Mika AK; Beno DW; Kempf-Grote AJ; Polakowski J; Segreti J; Reinhart GA; Fryer RM; Sham HL; Trevillyan JM
J Med Chem; 2006 Oct; 49(21):6416-20. PubMed ID: 17034148
[TBL] [Abstract][Full Text] [Related]
19. A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors.
Lu IL; Tsai KC; Chiang YK; Jiaang WT; Wu SH; Mahindroo N; Chien CH; Lee SJ; Chen X; Chao YS; Wu SY
Eur J Med Chem; 2008 Aug; 43(8):1603-11. PubMed ID: 18207285
[TBL] [Abstract][Full Text] [Related]
20. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
